Vitamins E and C in the Prevention of Cardiovascular Disease in Men: The Physicians' Health Study II Randomized Controlled Trial | Cardiology | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.175.212.130. Please contact the publisher to request reinstatement.
1.
Timbo BB, Ross MP, McCarthy PV, Lin CT. Dietary supplements in a national survey: prevalence of use and reports of adverse events.  J Am Diet Assoc. 2006;106(12):1966-197417126626PubMedGoogle ScholarCrossref
2.
Radimer K, Bindewald B, Hughes J, Ervin B, Swanson C, Picciano MF. Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000.  Am J Epidemiol. 2004;160(4):339-34915286019PubMedGoogle ScholarCrossref
3.
Muth MK, Anderson DW, Domanico JL, Smith JB, Wendling B. Economic Characterization of the Dietary Supplement Industry. Washington, DC: Center for Food Safety and Administration, Food and Drug Administration; 1999
4.
Packer L. Protective role of vitamin E in biological systems.  Am J Clin Nutr. 1991;53(4):(suppl)  1050S-1055S2012017PubMedGoogle Scholar
5.
Steinberg D, Lewis A. Conner memorial lecture: oxidative modification of LDL and atherogenesis.  Circulation. 1997;95(4):1062-10719054771PubMedGoogle ScholarCrossref
6.
Steiner M. Vitamin E, a modifier of platelet function: rationale and use in cardiovascular and cerebrovascular disease.  Nutr Rev. 1999;57(10):306-30910575906PubMedGoogle ScholarCrossref
7.
Mabile L, Bruckdorfer KR, Rice-Evans C. Moderate supplementation with natural alpha-tocopherol decreases platelet aggregation and low-density lipoprotein oxidation.  Atherosclerosis. 1999;147(1):177-18510525139PubMedGoogle ScholarCrossref
8.
Mehta J, Li D, Mehta JL. Vitamins C and E prolong time to arterial thrombosis in rats.  J Nutr. 1999;129(1):109-1129915884PubMedGoogle Scholar
9.
Andrews TJ, Laight DW, Anggard EE, Carrier MJ. Investigation of endothelial hyperreactivity in the obese Zucker rat in situ: reversal by vitamin E.  J Pharm Pharmacol. 2000;52(1):83-8610716607PubMedGoogle ScholarCrossref
10.
Koh KK, Blum A, Hathaway L,  et al.  Vascular effects of estrogen and vitamin E therapies in postmenopausal women.  Circulation. 1999;100(18):1851-185710545428PubMedGoogle ScholarCrossref
11.
Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men.  N Engl J Med. 1993;328(20):1450-14568479464PubMedGoogle ScholarCrossref
12.
Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women.  N Engl J Med. 1993;328(20):1444-14498479463PubMedGoogle ScholarCrossref
13.
Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, Bostick RM. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women.  N Engl J Med. 1996;334(18):1156-11628602181PubMedGoogle ScholarCrossref
14.
Klipstein-Grobusch K, Geleijnse JM, den Breeijen JH,  et al.  Dietary antioxidants and risk of myocardial infarction in the elderly: the Rotterdam Study.  Am J Clin Nutr. 1999;69(2):261-2669989690PubMedGoogle Scholar
15.
Enstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population.  Epidemiology. 1992;3(3):194-2021591317PubMedGoogle ScholarCrossref
16.
Ascherio A, Rimm EB, Hernan MA,  et al.  Relation of consumption of vitamin E, vitamin C, and carotenoids to risk for stroke among men in the United States.  Ann Intern Med. 1999;130(12):963-97010383366PubMedGoogle ScholarCrossref
17.
Messerer M, Hakansson N, Wolk A, Akesson A. Dietary supplement use and mortality in a cohort of Swedish men.  Br J Nutr. 2008;99(3):626-63117764599PubMedGoogle ScholarCrossref
18.
Buijsse B, Feskens EJ, Kwape L, Kok FJ, Kromhout D. Both alpha- and beta-carotene, but not tocopherols and vitamin C, are inversely related to 15-year cardiovascular mortality in Dutch elderly men.  J Nutr. 2008;138(2):344-35018203902PubMedGoogle Scholar
19.
Knekt P, Ritz J, Pereira MA,  et al.  Antioxidant vitamins and coronary heart disease risk: a pooled analysis of 9 cohorts.  Am J Clin Nutr. 2004;80(6):1508-152015585762PubMedGoogle Scholar
20.
Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group.  The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers.  N Engl J Med. 1994;330(15):1029-10358127329PubMedGoogle ScholarCrossref
21.
Leppälä JM, Virtamo J, Fogelholm R,  et al.  Controlled trial of alpha-tocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers.  Arterioscler Thromb Vasc Biol. 2000;20(1):230-23510634823PubMedGoogle ScholarCrossref
22.
Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS).  Lancet. 1996;347(9004):781-7868622332PubMedGoogle ScholarCrossref
23.
Virtamo J, Rapola JM, Ripatti S,  et al.  Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease.  Arch Intern Med. 1998;158(6):668-6759521232PubMedGoogle ScholarCrossref
24.
Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.  Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial.  Lancet. 1999;354(9177):447-45510465168PubMedGoogle ScholarCrossref
25.
Boaz M, Smetana S, Weinstein T,  et al.  Secondary Prevention with Antioxidants of Cardiovascular Disease in Endstage Renal Disease (SPACE): randomised placebo-controlled trial.  Lancet. 2000;356(9237):1213-121811072938PubMedGoogle ScholarCrossref
26.
Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P.Heart Outcomes Prevention Evaluation Study Investigators.  Vitamin E supplementation and cardiovascular events in high-risk patients.  N Engl J Med. 2000;342(3):154-16010639540PubMedGoogle ScholarCrossref
27.
Lonn E, Bosch J, Yusuf S,  et al.  Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial.  JAMA. 2005;293(11):1338-134715769967PubMedGoogle ScholarCrossref
28.
Cook NR, Albert CM, Gaziano JM,  et al.  A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study.  Arch Intern Med. 2007;167(15):1610-161817698683PubMedGoogle ScholarCrossref
29.
Blendon RJ, DesRoches CM, Benson JM, Brodie M, Altman DE. Americans' views on the use and regulation of dietary supplements.  Arch Intern Med. 2001;161(6):805-81011268222PubMedGoogle ScholarCrossref
30.
de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice: Collaborative Group of the Primary Prevention Project.  Lancet. 2001;357(9250):89-9511197445PubMedGoogle ScholarCrossref
31.
Lee IM, Cook NR, Gaziano JM,  et al.  Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial.  JAMA. 2005;294(1):56-6515998891PubMedGoogle ScholarCrossref
32.
Blot WJ, Li JY, Taylor PR,  et al.  Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease- specific mortality in the general population.  J Natl Cancer Inst. 1993;85(18):1483-14928360931PubMedGoogle ScholarCrossref
33.
Brown BG, Zhao XQ, Chait A,  et al.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.  N Engl J Med. 2001;345(22):1583-159211757504PubMedGoogle ScholarCrossref
34.
 MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial.  Lancet. 2002;360(9326):23-3312114037PubMedGoogle ScholarCrossref
35.
Hercberg S, Galan P, Preziosi P,  et al.  The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals.  Arch Intern Med. 2004;164(21):2335-234215557412PubMedGoogle ScholarCrossref
36.
Niki E. Interaction of ascorbate and alpha-tocopherol.  Ann N Y Acad Sci. 1987;498:186-1993304060PubMedGoogle ScholarCrossref
37.
Christen WG, Gaziano JM, Hennekens CH. Design of Physicians' Health Study II—a randomized trial of beta- carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials.  Ann Epidemiol. 2000;10(2):125-13410691066PubMedGoogle ScholarCrossref
38.
Steering Committee of the Physicians' Health Study Research Group.  Final report on the aspirin component of the ongoing Physicians' Health Study.  N Engl J Med. 1989;321(3):129-1352664509PubMedGoogle ScholarCrossref
39.
Hennekens CH, Buring JE, Manson JE,  et al.  Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease.  N Engl J Med. 1996;334(18):1145-11498602179PubMedGoogle ScholarCrossref
40.
Lang JM, Buring JE, Rosner B, Cook N, Hennekens CH. Estimating the effect of the run-in on the power of the Physicians' Health Study.  Stat Med. 1991;10(10):1585-15931947514PubMedGoogle ScholarCrossref
41.
Walker AE, Robins M, Weinfeld FD. The national survey of stroke: clinical findings.  Stroke. 1981;12:(2 pt 2 suppl 1)  I13-I447222164PubMedGoogle Scholar
42.
Berger K, Kase CS, Buring JE. Interobserver agreement in the classification of stroke in the Physicians' Health Study.  Stroke. 1996;27(2):238-2428571416PubMedGoogle ScholarCrossref
43.
Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis.  JAMA. 2007;297(8):842-85717327526PubMedGoogle ScholarCrossref
44.
Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases.  Cochrane Database Syst Rev. 2008;(2):CD00717618425980PubMedGoogle Scholar
45.
Miller ER III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality.  Ann Intern Med. 2005;142(1):37-4615537682PubMedGoogle ScholarCrossref
46.
de Gaetano G.Collaborative Group of the Primary Prevention Project.  Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice.  Lancet. 2001;357(9250):89-9511197445PubMedGoogle ScholarCrossref
47.
Lippman SM, Goodman PJ, Klein EA,  et al.  Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT).  J Natl Cancer Inst. 2005;97(2):94-10215657339PubMedGoogle ScholarCrossref
48.
Gilman AS, Goodman LS, Rall TW, Murad F. The Pharmacological Basis of Therapeutics. 7th ed. London, England: MacMillan; 1985:1586-1589
49.
Traber MG, Atkinson J. Vitamin E, antioxidant and nothing more.  Free Radic Biol Med. 2007;43(1):4-1517561088PubMedGoogle ScholarCrossref
50.
Dietrich M, Traber MG, Jacques PF, Cross CE, Hu Y, Block G. Does gamma-tocopherol play a role in the primary prevention of heart disease and cancer? a review.  J Am Coll Nutr. 2006;25(4):292-29916943450PubMedGoogle ScholarCrossref
51.
Hensley K, Benaksas EJ, Bolli R,  et al.  New perspectives on vitamin E: gamma-tocopherol and carboxyelthylhydroxychroman metabolites in biology and medicine.  Free Radic Biol Med. 2004;36(1):1-1514732286PubMedGoogle ScholarCrossref
52.
Robinson I, de Serna DG, Gutierrez A, Schade DS. Vitamin E in humans: an explanation of clinical trial failure.  Endocr Pract. 2006;12(5):576-58217002935PubMedGoogle ScholarCrossref
53.
Ford ES, Ajani UA, Mokdad AH. Brief communication: the prevalence of high intake of vitamin E from the use of supplements among US adults.  Ann Intern Med. 2005;143(2):116-12016027453PubMedGoogle ScholarCrossref
54.
Tardif JC, Cote G, Lesperance J,  et al; Multivitamins and Probucol Study Group.  Probucol and multivitamins in the prevention of restenosis after coronary angioplasty.  N Engl J Med. 1997;337(6):365-3729241125PubMedGoogle ScholarCrossref
55.
Tomoda H, Yoshitake M, Morimoto K, Aoki N. Possible prevention of postangioplasty restenosis by ascorbic acid.  Am J Cardiol. 1996;78(11):1284-12868960592PubMedGoogle ScholarCrossref
56.
Salonen RM, Nyyssonen K, Kaikkonen J,  et al.  Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study.  Circulation. 2003;107(7):947-95312600905PubMedGoogle ScholarCrossref
57.
Waters DD, Alderman EL, Hsia J,  et al.  Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial.  JAMA. 2002;288(19):2432-244012435256PubMedGoogle ScholarCrossref
58.
Hampl JS, Taylor CA, Johnston CS. Vitamin C deficiency and depletion in the United States: the Third National Health and Nutrition Examination Survey, 1988 to 1994.  Am J Public Health. 2004;94(5):870-87515117714PubMedGoogle ScholarCrossref
59.
Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board.  Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Beta-carotene, and Other Carotenoids. Washington, DC: National Academy Press; 2000
60.
Li Y, Schellhorn HE. New developments and novel therapeutic perspectives for vitamin C.  J Nutr. 2007;137(10):2171-218417884994PubMedGoogle Scholar
Original Contribution
November 12, 2008

Vitamins E and C in the Prevention of Cardiovascular Disease in Men: The Physicians' Health Study II Randomized Controlled Trial

Author Affiliations

Author Affiliations: Divisions of Preventive Medicine (Drs Sesso, Buring, Christen, Kurth, Bubes, Manson, Glynn, and Gaziano and Mss Belanger and MacFadyen), Aging (Drs Sesso, Buring, Kurth, and Gaziano), and Cardiovascular Disease (Dr Gaziano), Department of Medicine, Brigham and Women's Hospital, and Department of Ambulatory Care and Prevention (Dr Buring), Harvard Medical School, and Department of Epidemiology (Drs Sesso, Buring, Kurth, and Manson), Harvard School of Public Health, Boston, Massachusetts; and VA Boston Healthcare System, Boston, Massachusetts (Dr Gaziano).

JAMA. 2008;300(18):2123-2133. doi:10.1001/jama.2008.600
Abstract

Context Basic research and observational studies suggest vitamin E or vitamin C may reduce the risk of cardiovascular disease. However, few long-term trials have evaluated men at initially low risk of cardiovascular disease, and no previous trial in men has examined vitamin C alone in the prevention of cardiovascular disease.

Objective To evaluate whether long-term vitamin E or vitamin C supplementation decreases the risk of major cardiovascular events among men.

Design, Setting, and Participants The Physicians' Health Study II was a randomized, double-blind, placebo-controlled factorial trial of vitamin E and vitamin C that began in 1997 and continued until its scheduled completion on August 31, 2007. There were 14 641 US male physicians enrolled, who were initially aged 50 years or older, including 754 men (5.1%) with prevalent cardiovascular disease at randomization.

Intervention Individual supplements of 400 IU of vitamin E every other day and 500 mg of vitamin C daily.

Main Outcome Measures A composite end point of major cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, and cardiovascular disease death).

Results During a mean follow-up of 8 years, there were 1245 confirmed major cardiovascular events. Compared with placebo, vitamin E had no effect on the incidence of major cardiovascular events (both active and placebo vitamin E groups, 10.9 events per 1000 person-years; hazard ratio [HR], 1.01 [95% confidence interval {CI}, 0.90-1.13]; P = .86), as well as total myocardial infarction (HR, 0.90 [95% CI, 0.75-1.07]; P = .22), total stroke (HR, 1.07 [95% CI, 0.89-1.29]; P = .45), and cardiovascular mortality (HR, 1.07 [95% CI, 0.90-1.28]; P = .43). There also was no significant effect of vitamin C on major cardiovascular events (active and placebo vitamin E groups, 10.8 and 10.9 events per 1000 person-years, respectively; HR, 0.99 [95% CI, 0.89-1.11]; P = .91), as well as total myocardial infarction (HR, 1.04 [95% CI, 0.87-1.24]; P = .65), total stroke (HR, 0.89 [95% CI, 0.74-1.07]; P = .21), and cardiovascular mortality (HR, 1.02 [95% CI, 0.85-1.21]; P = .86). Neither vitamin E (HR, 1.07 [95% CI, 0.97-1.18]; P = .15) nor vitamin C (HR, 1.07 [95% CI, 0.97-1.18]; P = .16) had a significant effect on total mortality but vitamin E was associated with an increased risk of hemorrhagic stroke (HR, 1.74 [95% CI, 1.04-2.91]; P = .04).

Conclusions In this large, long-term trial of male physicians, neither vitamin E nor vitamin C supplementation reduced the risk of major cardiovascular events. These data provide no support for the use of these supplements for the prevention of cardiovascular disease in middle-aged and older men.

Trial Registration clinicaltrials.gov Identifier: NCT00270647

Trial Registration Published online November 9, 2008 (doi: 10.1001/jama.2008.600).

×